医学
上市后监督
类风湿性关节炎
临床试验
特应性皮炎
怀孕
人口
斑秃
皮肤病科
不利影响
内科学
环境卫生
遗传学
生物
作者
Barbara Maria Bergamini,Julien Séneschal,Kristin J. Meyers,Frédérick Durand,Ewa Haładyj,Gerard Espinosa,Jacob P. Thyssen
摘要
Information is needed to manage pregnancies with inadvertent exposure to baricitinib. A total of 117 pregnancies with exposure to baricitinib were identified among patients treated with baricitinib for rheumatoid arthritis, atopic dermatitis, or alopecia areata during clinical trials or in the postmarketing setting, and retrieved from the Eli Lilly global safety database. The clinical outcomes of the pregnancies with reported exposure to baricitinib appear to be comparable to those previously reported with other targeted therapies for immune-mediated diseases or in the general population.
科研通智能强力驱动
Strongly Powered by AbleSci AI